{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"154"}]}],"title":"Low (<10%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"650"}]}],"title":"Medium (10-20%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"640"}]}],"title":"High (>20%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1447"}],"units":"Participants"}],"description":"Objective 1: To describe the cancer patients requiring chemotherapy who, in their treating physician's best clinical judgment, are receiving EP2006 for the primary or secondary prophylaxis of FN in terms of demographics, clinical status, medical history, concomitant comorbid conditions and current status of disease, and prior and concomitant medications.\n\nChemotherapy regimens were classified for FN risk (\\<10% risk, 10-20% risk or \\>20% risk) according to the published rates in the EORTC Guidelines under consideration of agent(s) and schedules.\n\nANC=Absolute Neutrophil Count; CIN=Chemotherapy-Induced Neutropenia; FN=Febrile Neutropenia;","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","populationDescription":"The evaluable sample includes all patients in the safety sample (all patients who received at least one dose of the study medication) who had no major protocol violation and have a minimum of enrollment cycle and either one follow-up cycle or study end data with valid outcome data. Please refer to baseline characteristics tables as well.","reportingStatus":"POSTED","timeFrame":"Enrollment cycle. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician.","title":"Chemotherapy Toxicity (%FN Risk)","type":"PRIMARY","unitOfMeasure":"participants"}